Validation of Biomarkers for Prostate Cancer Prognosis
Abstract
Our objective is to create a multi-institutional tissue microarray resource from radical prostatectomy samples with detailed clinical information and follow-up and rigorous casecohort design for use as a platform for validating tissue biomarkers of prognosis. In addition, we have proposed testing a series of biomarkers of prognosis and a set of biomarkers that correlate with Gleason Score. We have made significant progress over the past year. We have completed the tissue microarrays and finalized standard procedures for tissue microarray storage, sectioning and shipping. We have set up a structure for reviewing and approving biomarker proposals based on sound scientific principles and strong preliminary data. We have devised and tested a centralized distribution mechanism at Stanford University of collating and shipping TMAs to participating sites, We have found shortcomings with the BLISS system and STMAD for histological image capture and storage for pathological review and have developed a much improved, highly efficient system using a Leica scanner and PathXL image analysis software suite. We also have made significant progress in testing TACOMA, an automater TMA scoring algorithm. We have completed staining of the TMAs for H & E, High Molecular Weight Keratin, p27, ERG, SPKINK1, Ki67 (MIB1), MUC1, Survivin and PTEN FISH. Over the next year we will carry out more staining, complete refinements of the infrastructure, complete pathologic review of these and other biomarkers, evaluate concordance of scoring of immunohistochemical staining amongst study pathologists and report (publish) our findings.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2012
- Accession Number
- ADA570054
Entities
People
- James D Brooks
- Ziding Feng
Organizations
- Stanford University